On November 4, 2025 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in two upcoming investor conferences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s participation are as follows:
Guggenheim 2nd Annual Healthcare Innovation Conference
Fireside Chat: Tuesday, November 11 at 9:00 a.m. ET
Jefferies Global Healthcare Conference
Fireside Chat: Tuesday, November 18 at 9:30 a.m. GMT
To listen to a live webcast of any of these events, or access archived webcasts, please visit: View Source Following the live webcasts, replays will be available on the company’s website for at least 14 days.
(Press release, Revolution Medicines, NOV 4, 2025, View Source [SID1234659372])